"Internal coasting" for prevention of ovarian hyperstimulation syndrome (OHSS) in IVF/ICSI

Ginekologia Polska

Volumn 82, Issue 11, 2011, Pages 812-816

  Lukaszuk, Krzysztof ^a,b   Liss, Joanna ^a   Jakiel, Grzegorz ^c  

^a INVICTA Fertility and Reproductive Center   (Poland)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

^c MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

Author keywords

Embryo transfer; In vitro fertilization; Internal coasting; Ovarian hyperstimulation syndrome; Ovarian stimulation

Indexed keywords

EID: 83455163861     PISSN: 00170011     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Mathur R, Hayman G, Bansal A, Jenkins J. Serum vascular endothelial growth factor levels are poorly predictive of subsequent ovarian hyperstimulation syndrome in highly responsive women undergoing assisted conception. Fertil Steril. 2002, 78, 1154-1158.
2. Delbaere A, Smits G, Olatunbosun O, [et al.]. New insights into the pathophysiology of ovarian hyperstimulation syndrome. What makes the difference between spontaneous and iatrogenic syndrome? Hum Reprod. 2004, 19, 486-489.
3. Navot D, Bergh P, Laufer N. The ovarian hyperstimulation syndrome. In: Reproductive Endocrinology, Surgery, and Technology. Eds. Adashi E, Rock J, Rosenwaks Z. Philadelphia: Lippincott-Raven Publishers. 1996, 2215-2232.
4. Delbaere A, Bergmann P, Gervy-Decoster C, [et al.]. Increased angiotensin II in ascites during severe ovarian hyperstimulation syndrome: role of early pregnancy and ovarian gonadotropin stimulation. Fertil Steril. 1997, 67, 1038-1045.
5. Levinsohn-Tavor O, Friedler S, Schachter M, [et al.]. Coasting-what is the best formula? Hum Reprod. 2003, 18, 937-940.
6. Homburg R, Insler V. Ovulation induction in perspective. Hum Reprod Update. 2002, 8, 449-462.
7. Humaidan P, Quartarolo J, Papanikolaou E. Preventing ovarian hyperstimulation syndrome: guidance for the clinician. Fertil Steril. 2010, 94, 389-400.
8. Grochowski D, Wolczynski S, Kuczynski W, [et al.]. Correctly timed coasting reduces the risk of ovarian hyperstimulation syndrome and gives good cycle outcome in an in vitro fertilization program. Gynecol Endocrinol. 2001, 15, 234-238.
9. Rizk, B, Aboulghar M. Modern management of ovarian hyperstimulation syndrome. Hum Reprod. 1991, 6, 1082-1087.
10. Ben-Chetrit A, Eldar-Geva T, Gal M, [et al.]. The questionable use of albumin for the prevention of ovarian hyperstimulation syndrome in an IVF programme: a randomized placebo-controlled trial. Hum Reprod. 2001, 16, 1880-1884.
11. Busso C, Fernández-Sánchez M, García-Velasco J, [et al.]. The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial. Hum Reprod. 2010, 25, 995-1004.
12. Venetis C, Kolibianakis E, Toulis K, [et al.]. Intravenous albumin administration for the prevention of severe ovarian hyperstimulation syndrome: a systematic review and metaanalysis. Fertil Steril. 2011, 95, 188-196.
13. Lukaszuk K, Liss J, Lukaszuk M, Maj B. Optimization of estradiol supplementation during the luteal phase improves the pregnancy rate in women undergoing in vitro fertilization-embryo transfer cycles. Fertil Steril. 2005, 83, 1372-1376.
14. Rizk B, Aboulghar M. Classification, pathophysiology and management of ovarian hyperstimulation syndrome. In: In-Vitro Fertilization and Assisted Reproduction. Ed. Brinsden P. New York-London: The Parthenon Publishing Group. 1999, 131-155.
15. Endo T, Honnma H, Hayashi T, [et al.]. Continuation of GnRH agonist administration for 1 week, after hCG injection, prevents ovarian hyperstimulation syndrome following elective cryopreservation of all pronucleate embryos. Hum Reprod. 2002, 17, 2548-2551.
16. D'Angelo A, Amso N. Embryo freezing for preventing Ovarian Hyperstimulation Syndrome. Hum Reprod. 2002, 17, 2787-2794.